| 0.719 0.06 (9.1%) | 04-23 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.93 | 1-year : | 1.19 |
| Resists | First : | 0.8 | Second : | 1.01 |
| Pivot price | 0.69 |
|||
| Supports | First : | 0.45 | Second : | 0.37 |
| MAs | MA(5) : | 0.68  |
MA(20) : | 0.72 |
| MA(100) : | 1.44 |
MA(250) : | 1.98 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 59.1 |
D(3) : | 54.4 |
| RSI | RSI(14): 43.3 |
|||
| 52-week | High : | 7.19 | Low : | 0.45 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ SLRX ] has closed below upper band by 36.8%. Bollinger Bands are 72.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 24 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.72 - 0.72 | 0.72 - 0.73 |
| Low: | 0.64 - 0.65 | 0.65 - 0.65 |
| Close: | 0.71 - 0.72 | 0.72 - 0.72 |
Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and biomarkers for SP-2577. The company is headquartered in Houston, Texas.
Wed, 16 Apr 2025
Decoy Therapeutics to Welcome MIT's Robert Langer to Advisory Board Post-Merger with Salarius (SLRX) | SLRX Stock News - GuruFocus
Fri, 28 Mar 2025
Salarius Amends Merger Terms, Faces Nasdaq Compliance Issue - Investing.com
Wed, 26 Mar 2025
Revolutionary AI Platform Discovers Multi-Target Antiviral in Just 5 Days - Stock Titan
Mon, 24 Mar 2025
Salarius Pharmaceuticals Reports 2024 Financial Results and Provides Business Update - GlobeNewswire
Fri, 21 Mar 2025
Salarius Pharmaceuticals, Inc. SEC 10-K Report - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 2 (M) |
| Shares Float | 2 (M) |
| Held by Insiders | 2 (%) |
| Held by Institutions | 4.7 (%) |
| Shares Short | 40 (K) |
| Shares Short P.Month | 10 (K) |
| EPS | -5.79 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.04 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -74.6 % |
| Return on Equity (ttm) | -164.1 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -3.32 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -5 (M) |
| Levered Free Cash Flow | -3 (M) |
| PE Ratio | -0.13 |
| PEG Ratio | 0 |
| Price to Book value | 0.68 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.28 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|